Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Pick a strategy above and run the backtest to see its simulated performance on GLUE.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
Monte Rosa Therapeutics (GLUE) is trading at $10.17, up 3.04% on the day. Its market value of $867.64M makes it the 3343rd largest of the 3753 companies we follow.
It is close to the bottom of its 52-week range ($8.94 to $25.77), 60.5% under the high. Holders are ahead 31.9% over twelve months, but down 58.5% across the last three months.
On the chart it has slipped under both the 50-day ($14.07) and 200-day ($18.09) moving averages; RSI is 25, which some call oversold, and the last 30 sessions moved at roughly 50% annualized volatility.
Revenue for the quarter ended Jun 2026 was $8.97M, down 61.3% from a year earlier, and a net loss of $43.40M.
7 analysts follow the stock and the average call is "buy". The mean target, $28.17, sits 177.0% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3752 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
7 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
GLUE is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $28.17, 177.0% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $10.38, so shares trade 2.1% below that estimate. On earnings multiple, it sits in the 12th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -15.4% | Bearish |
| Price vs 50-day average | -27.7% | Bearish |
| Price vs 200-day average | -43.8% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 25.5 | Neutral |
| MACD (12,26,9) | -1.19 | Bearish |
| Bollinger band position | 13% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 8, 2026 7:30 am ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,752 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$10.17 is the latest print for GLUE, a move of +3.04% against yesterday's close of $9.87. Today's low and high so far: $9.68 and $10.75.
Equity value comes to $867.64M at the current price. By that measure it is number 3343 of the 3753 names in our coverage.
The year's floor is $8.94 and the ceiling $25.77. Shares are 60.5% away from that ceiling.
Our data shows no dividend paid by Monte Rosa Therapeutics over the trailing twelve months.
Of 7 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $28.17, with the most cautious at $25.00 and the most optimistic at $37.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on GLUE.